Search

Kymera Therapeutics Inc

Suletud

SektorTervishoid

117.35 3.11

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

111.89

Max

117.97

Põhinäitajad

By Trading Economics

Sissetulek

8M

-61M

Müük

31M

65M

Aktsiakasum

-0.62

Kasumimarginaal

-94.171

Töötajad

273

EBITDA

6M

-61M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+14.78% upside

Dividendid

By Acuity

Järgmine tulemuste avaldamine

3. nov 2026

Turustatistika

By TradingEconomics

Turukapital

777M

9B

Eelmine avamishind

114.24

Eelmine sulgemishind

117.35

Kymera Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

14. aug 2026, 20:06 UTC

Kymera Therapeutics Inc shares are higher today, recovering from an earlier pullback amid a mixed market backdrop following a decline in U.S. retail sales.

12. aug 2026, 20:01 UTC

Kymera Therapeutics Inc shares are trading higher amid increased activity and unusually high market volume, with no specific news identified to explain the movement.

6. aug 2026, 19:56 UTC

Kymera Therapeutics Inc shares are lower today, trading near the lower end of their one-month range amid broader market dynamics and inflationary concerns.

5. aug 2026, 20:02 UTC

Social Media
News

Kymera Therapeutics reported a narrower net loss of $61.21 million for Q2 2026, driven by increased collaboration revenue and a price target raise from Stifel to $132.

4. aug 2026, 20:04 UTC

Correlated Moves

Kymera Therapeutics Inc is rising in Tuesday's session, reflecting bullish sentiment in the biotechnology sector amid a broader market uptrend.

3. aug 2026, 19:46 UTC

News

Kymera Therapeutics Inc shares are lower amid volatility, following Dimensional Fund Advisors LP's 5% stake reduction and broader market trends in biotechnology.

31. juuli 2026, 20:06 UTC

Correlated Moves

Kymera shares lower amid SPDR S&P Biotech ETF decline.

30. juuli 2026, 19:39 UTC

Kymera Therapeutics Inc shares are higher during Thursday's session, with no specific news identified to explain the price action amid broader market trends.

29. juuli 2026, 19:32 UTC

Macro Event

Kymera Therapeutics shares are higher as the Federal Reserve maintains rates at 3.50%–3.75%. Investors monitor inflation trends and their impact on future policy.

28. juuli 2026, 17:42 UTC

News
Social Media

Shares lower despite Guggenheim's price target increase to $135.

27. juuli 2026, 21:03 UTC

News

Kymera Therapeutics shares are lower in after-market hours following the appointment of Terence Rooney, MD, as Chief Medical Officer, succeeding Jared Gollob, MD.

24. juuli 2026, 18:46 UTC

Kymera Therapeutics Inc. shares are roughly flat as trading fluctuates within a narrow range, reflecting routine activity without specific news.

21. juuli 2026, 19:16 UTC

Kymera Therapeutics Inc is trading higher, supported by broader market strength and optimism in AI stocks, despite a pullback earlier in the session.

20. juuli 2026, 22:16 UTC

Kymera Therapeutics Inc shares are lower in after-market hours. Broader market sentiment is influenced by rising Treasury yields amid interest rate and geopolitical concerns.

Võrdlus sarnastega

Hinnamuutus

Kymera Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

14.78% tõus

12 kuu keskmine prognoos

Keskmine 131.33 USD  14.78%

Kõrge 155 USD

Madal 112 USD

Põhineb 18 Wall Streeti analüütiku instrumendi Kymera Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

18 ratings

16

Osta

2

Hoia

0

Müü

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Kymera Therapeutics Inc

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
help-icon Live chat